Blinatumomab for First-Line Treatment of Children and Young Persons with B-ALL
Data were collected for consecutive children and young persons aged 1-24 years with Philadelphia chromosome–positive or Philadelphia chromosome–negative B-ALL who received blinatumomab as first-line therapy.
[Biogerontology] Investigators explored the possibility of inducing aging-associated features in cell types of the central nervous system using hiPSC technology.
[Journal Of Neuroscience] The authors reported using human tumor specimens and primary spheroids from male and female patients that GlialCAM, was differentially expressed in subpopulations of glioblastoma cells.
[Molecular Psychiatry] Investigators showed that the PTENG132D allele disrupted early neuroectoderm formation during the first several days of organoid generation, and results in deficient electrophysiology.